Exclusive interview

Complex manufacturing more likely kept in-house, says J&J post Ben Venue

Janssen Biologics invested in-house in Cork, Ireland, but says less complex manufacture more likely to be outsourced

Outsourcing is still a significant part of Janssen’s strategy, the firm says despite suffering shortages due to manufacturing and quality problems at now defunct CMO Ben Venue.

The Johnson & Johnson unit was perhaps the highest profile firm affected by the quality failures at contract manufacturer Ben Venue Laboratories which culminated in a US Food and Drug Administration (FDA) consent decree and a decision by owners Boehringer Ingelheim to close the Bedford, Ohio site at the end of last year.

Janssen had previously suffered shortages of its ovarian cancer drug Doxil after relying on the CMO as its sole supplier, and therefore took over the site earlier this year for a six month tenure to continue manufacturing under authorisation from the US District Court of Northern Ohio and the FDA.

With the lease will soon run out – and the facility’s future up in the air following Hikma’s exclusive right to buy the Ben Venue assets as part of its acquisition of parent firm Bedford Labs last week – we spoke with Kyran Johnson, General Manager of supply chain in Ireland, to see how Janssen’s outsourcing strategy had moved on.

“There is certainly a perspective that if you go to outsourcing manufacturing, you lose control over it and you’ve got companies that maybe don’t have the same standards as yourself, but I think that’s changing,” he told Outsourcing-Pharma.com.

“I think that J&J more than perhaps any other company realise that we’re responsible for the products and the supply to the market, whether we manufacture ourselves or whether we manufacture through a third party.”

Johnson said that Janssen needs to ensure that the CMOs it works with can demonstrate they have the same capability, technically and in compliance with cGMP, as at its internal sites, adding that the company is looking to ensure it “has a robust process in terms of our external suppliers, and make sure we have the systems in place to assess and support, and make sure they can meet those requirements.”

Though not directly involved with the Ben Venue saga Johnson told us it “has been a real problem and a real issue for the company as to how we can sort that out,” whilst confirming a new supplier is currently coming on line.

In-house Complexity

Whilst J&J’s outsourcing strategy depends on a number of variables and is both product and platform dependent, Johnson said the firm still did a “significant amount of outsourcing of manufacturing of small molecule because the capacity is there.”

However, for biologics and more complex production techniques, Janssen would be more likely to invest in its own capabilities due to the level of technology and experience not being available from third-parties.

“You look at the product you’re going to make, the technology involved, the value of it and then you are assessing if this is a technology we need to build in-house expertise, or is it well-established out there,” he expalined, adding Janssen – like other Big Pharma – is limited by its capital expenditure.

“Are you going to put that into your high value more complex technology pieces, rather than taking something that’s being produced using certain technologies that’s been there for many years? It’s a lot less risk to do that.”

Fellow Big Pharma firm Eli Lilly told this publication recently it was taking greater control of its in-house production as manufacturing becomes more complex.

Related News

Hikma buys Boehringer Ingeleheim CMO Ben Venue Labs

Ben Venue assets will bolster sterile injectables network, says Hikma

Ben Venue site has no place in injectables network, says Hikma

Ben Venue site has no place in injectables network, says new owner Hikma

Novartis will continue to outsource the 'easy side' of manufacturing but complex biologics stay in-house

Novartis to keep complex biologics manufacturing in-house

Ex-Doxil producer Ben Venue could be sold as option in Hikma's $300m Bedford Labs acquisition

Hikma eyes Ben Venue's assets as part of $300m Bedford Labs acquistion

Bedford, Ohio

Plan to lease Doxil space at Ben Venue to J&J needs approval says BI

Janssen Releases Additional Doxil via Alternate Manufacturing Approach

Janssen Releases Additional Doxil Lot via Alternative Manufacturing Approach

Doxil shortage over with new CMO approach

Janssen says 'alternative manufacturing' will restore doxil supplies; Ben Venue gets consent decree

What next for Ben Venue's Bedford, Ohio site?

Ben Venue closure: Company evaluates facility, EMA evaluates shortages

Ben Venue restarts limited manufacturing

Ben Venue restarts production; Janssen says Doxil available soon

Ben Venue is having more manufacturing issues

More Ben Venue manufacturing issues will lead to Doxil shortages in October

Ben Venue's consent decree was necessary says FDA; limited manufacturing to continue

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.